The strategy of modulating gene activities in vivo via CRE/loxP recombination would greatly pro®t from subjecting the recombination event to an independent and stringent temporal control. Here, we describe a transgenic mouse line, LC-1, where the expression of the cre and luciferase gene is tightly controlled by the Tet system. Using the R26R mouse line as indicator for CRE activity, and mouse lines expressing tetracycline controlled transactivators (tTA/rtTA) in various tissues, we show that; (i) in the non-induced state CRE recombinase is tightly controlled throughout the development and adulthood of an animal; (ii) upon induction, ef®cient recombination occurs in the adult animal in all tissues where tTA/rtTA is present, including hepatocytes, kidney cells, neurons and T lymphocytes; and (iii) no position effect appears to be caused by the LC-1 locus. Moreover, using the novel rTA LAP -1 mouse line, we show that in hepatocytes, complete deletion of the loxP-¯anked insert in R26R animals is achieved less than 48 h after induction. Thus, the LC-1 mouse appears suitable for exploiting two rapidly increasing collections of mouse lines of which one provides tTA/rtTA in speci®c cell types/ tissues, and the other a variety of loxP-¯anked genes.
INTRODUCTION
Site-speci®c recombinases, such as CRE and FLP derived from microorganisms, catalyze recombination between their cognate recognition sites, loxP and frt, respectively, with high speci®city. Both systems function in mammalian cells and, in particular, the CRE/loxP system has developed into a powerful tool for the in vivo manipulation of genomes in transgenic mice (reviewed in 1±3). While the recombinases permit to invert or delete DNA fragments in cis or switch segments of DNA in trans and thus allow a variety of modi®cations, including chromosome engineering, the most common application is the conditional deletion of a DNA fragment¯anked, e.g., by two loxP sites in order to silence or activate a gene. In the most generally applied approach, conditionality of recombination is based on the speci®city of the promoter driving the expression of the cre gene and, accordingly, recombination will occur dependent on the spatial and temporal activity of the respective promoter. Not withstanding its great potential, this approach has a number of limitations. Thus, the activity spectrum of a promoter depends on a rigid developmental/differentiation program of an organism and, accordingly, as recombination induces irreversible alterations, the ®nal pattern of CRE action will re¯ect the`history' of a promoter's activity throughout development. While such a cummulative recombination pattern may be of interest in some studies, it diminishes the precision of the approach in others. Moreover, as CRE will act whenever a respective promoter becomes active in a particular tissue/cell type, it will not be possible to induce recombination at a later time in the lifespan of an animal, thus preventing a thorough study of the unperturbed state in the same individual. Finally, there is increasing evidence that by recognizing pseudo loxP sites within the mouse genome, CRE can cause undesired recombination events (4, 5) . Even if such recombinations occur at a low rate, the outcome will depend on the intracellular concentration of CRE and the duration of its expression.
Obviously, controlling CRE activity from outside at will would enhance the scope of the technology signi®cantly as numerous attempts demonstrate. Two approaches have primarily been followed (reviewed in 2): controlling either the transcription of the cre gene or the activity of CRE itself. Both principles have been applied with some success, but problems concerning the general applicability have remained. They were connected with the inducers of the control systems (interferon, synthetic steroids such as tamoxifen and Ru486), the diminished enzymatic activity of the CRE fusion proteins and the tightness of the control systems over long periods of time. The latter parameter is particularly important in the study of long-lived cells as recombination events, caused by leakiness of the control system, accumulate over time.
When properly set up, the Tet regulatory system allows tight control of transcription (6, 7) and indeed control of CRE via doxycycline (Dox) has been reported (8±10). The approach of Utomo et al. (9) seems particularly attractive in this context. Here, a single vector encodes two transcription units, of which one contains the gene of a tetracycline controlled transactivator (tTA or rtTA) driven by a cell type speci®c promoter, whereas the other one encodes CRE controlled by the tTA/ rtTA responsive promoter P tet -1 (7) . Mouse lines derived with this vector were shown to control CRE activity satisfactorily in the expected tissues. Nevertheless, like other regulatory systems which function via promoter activation, the tightness and range of regulation of the Tet system depends strictly on the genomic locus where the P tet controlled transcription unit is integrated. For example, enhancers which may act over considerable distances can activate the minimal promoter within P tet when located near the integration site. One would, therefore, predict that the Utomo vector will function in some, but not in other settings.
Here, we describe an alternative strategy which is based on a mouse line, designated LC-1, that contains a P tet -cre transcription unit integrated in an appropriate chromosomal locus and which exhibits remarkable properties: when used to generate triple transgenic animals,which also contain the lacz gene silenced by a loxP¯anked Stop sequence (ROSA R26R line) and which produce rtTA or tTA in various tissues, no CRE mediated recombination is detected via X-gal staining in the uninduced state during development and during at least 14 months of adulthood. In contrast, upon induction, ef®cient recombination occurs in all tissues examined. Moreover, there is apparently no position effect variegation (PEV) connected with the LC-1 locus.
Considering the rapidly increasing number of mouse lines producing tTA or rtTA in a wide variety of tissues/cell types (reviewed in 11) and the large`zoo' of mouse lines with loxPanked genes (12), the LC-1 line will allow researchers to exploit both pools to generate animals where CRE activity is subjected to Tet control. Even though the breeding of triple transgenic mice will be somewhat demanding, it permits, however, to obtain the desired animals without generating and characterizing a new transgenic line.
MATERIALS AND METHODS

DNA constructs
The bidirectional transcripton unit (Fig. 1) encoding the cre and the luciferase (luc) gene under the control of the promoter P tet bi-1 (7,13) was derived as described previously (14) . The sequence of the transcription unit is available upon request.
The P LAP rtTA2 s -S2 transcription unit ( Fig. 1 ) was obtained by ®rst replacing the SV40 poly(A) site in pUHrT61-1 (15) by the b-globin intron/poly(A) sequence. Subsequently, the P CMV sequence was exchanged for the sequence encoding the promoter of the liver enriched activator protein (16) derived from plasmid pUHG15-30 (17) . Sequence information for the resulting plasmid pUHrT61-30 is available upon request.
Generation of transgenic mice
LC transgenic mice were obtained by pronuclear injection of a puri®ed 6.8 kb NotI fragment containing the bidirectional transcription unit into fertilized F2 (C57Bl/6X BALB/c) eggs. Similary, rTA LAP mice were generated by transferring the 5.1 kb XmnI±AsnI fragment of pUHrT61-30 into fertilized F2 (C57Bl/6X DBA) eggs, following standard techniques (18) .
Genotypes were identi®ed by Southern blot analyses and PCR using DNA from tail biopsies. Probes for Southern blot analyses were, for LC animals, the 1.25 kb SalI fragment from PTZ19Rcre NLS -1 (14) , and for rTA LAP mice, the 0.75 kb XbaI±BamHI fragment from pUHrT 61-1.
For PCR analyses, the following primers were designed. luc: sense luc1, 5¢-TTA CAG ATG CAC ATA TCG AGG-3¢; antisense luc2, 5¢-TAA CCC AGT AGA TCC AGA GG-3¢. cre: sense Cre3, 5¢-TCG CTG CAT TAC CGG TCG ATG C-3¢; antisense Cre4, 5¢-CCA TGA GTG AAC GAA CCT GGT CG-3¢. TetR (synthetic): sense sTA, 5¢-CCA TGT CTA GAC TGG ACA AGA-3¢; antisense sTA, 5¢-CTC CAG GCC ACA TAT GAT TAG-3¢. tetR (native): sense tet, 5¢-AAT GAG GTC GGA ATC GAA GG-3¢; antisense tet, 5¢-TAG CTT GTC GTA ATA ATG GCG G-3¢. internal lacZ: sense lacZ, 5¢-TTA CGA TGC GCC CAT CTA CAC-3¢; antisense lacZ, 5¢-TTA CCC GTA GGT AGT CAC GCA-3¢.
PCR was routinely carried out for 28 cycles and resulting material was analyzed by electrophoresis in agarose (1%).
Doxycycline treatment
Double or triple transgenic animals were supplied for two weeks with doxycycline hydrochloride via drinking water (5% sucrose, 0.2±2 mg Dox/ml) which was exchanged twice a week. For rapid and short-lived induction, 2 mg of Dox in 0.5 ml of 0.9% aqueous NaCl were injected i.p. Depending on the experiment, injections were repeated twice at intervals of 24 h. 
Luciferase assay
Tissue samples of transgenic animals were processed and luciferase activity determined as described previously (17) .
Histology
In situ b-galactosidase staining. Sacri®ced mice were perfused ®rst with PBS followed by 4% paraformaldehyde in PBS. Tissue samples were incubated overnight in PBS containing 30% sucrose and subsequently frozen on dry ice. To detect lacz expression 20 mm cryosections mounted on glass slides (SuperFrost Plus, Menzel-Gla Èser) were stained with 4-bromo-3-chloro-2-indolyl-b-galactosidase overnight at 37°C (18) . A 0.1% Nuclear fast red-solution (Certistain, MERCK) in 5% aqueous aluminium sulfate solution was used for counterstaining.
Immunohistochemistry. Brain immunohistochemistry of CRE recombinase was carried out as described by Kellendonk et al. (19) . Liver slices were processed as 20 mm cryosections mounted on glass slides.
PCR analysis
For detecting recombination in the R26R allele, the following primers were used: R26F2 (5¢-AAAGTCGCTCTGAGT-TGTTAT-3¢) as described by Soriano (20) and a modi®cation of lacZ3 (21) designed in our lab (lacZ4, 5¢-GTGCGG-GCCTCTTCGCTAT-3¢). With these primers the intact R26R allele gives rise to an~3.5 kb fragment which is reduced upon CRE mediated recombination to 600 bp. DNA from ®xed tissue samples used for in situ b-gal staining was puri®ed by the DNeasy Tissue Kit from Qiagen. PCR conditions were as follows: 5 min at 94°C, 38 cycles of 40 s at 94°C, 40 s at 58°C and 90 s at 68°C, followed by 7 min at 68°C. Taq polymerase was purchased from Roche Diagnostics GmbH (Expand High Fidelity PCR System). According to Rijnkels and Rosen (21), such DNA is only suitable for identifying PCR products of up to 800 bp. The lacz gene was identi®ed analogously using internal primers (see above).
RESULTS
Generation of a mouse line controlling CRE recombinase
To facilitate the identi®cation of founder lines where the cre gene is regulated tightly and over a suitable range, the bidirectional promoter P tet bi-1 (13) was used to coregulate the cre and the luc gene (Fig. 1) . Upon transfer of the respective DNA construct into mice, seven founder lines were obtained which transmitted the transgene stably. Animals of these lines were crossed with rTA CMV -3 mice which produce rtTA in all organs where the activity of the human cytomegalovirus promoter IE (P hCMV ) is supported (Fig. 2) including muscle, pancreas, thymus, kidney and spleen (17) . Monitoring the luciferase activity in the various organs in presence and absence of Dox revealed the LC-1 line (TCL-1, in 14) as a most promising one: in the OFF state, i.e. in absence of Dox, luciferase activity was barely or not at all detected in any organ. In contrast, when Dox was supplied (2 mg/ml in drinking water), it was induced to levels re¯ecting the activity of P hCMV in the respective organs (Fig. 2) . Moreover, when LC-1 mice were crossed with animals of the TA LAP -2 line (17), a hepatocyte speci®c tTA mouse line, luciferase was induced to high levels exclusively in the liver (Fig. 2) . In all other lines, luciferase was also barely detectable in the uninduced state. However, it was inducible to only low levels when compared to LC-1. One of these lines expressed the cre transgene transiently during embryonal development, mediating the complete deletion of loxP-¯anked substrates even in the absence of the rtTA transgene (22) .
Generation of a mouse line expressing rtTA2 S -S2 under the control of the LAP promoter
The promoter of the liver enriched activator protein, P LAP (16) , can give rise to hepatocyte speci®c expression when ectopically inserted in transgenic mice, as previously shown with the mouse lines TA LAP -1 and TA LAP -2 (17) which produce tTA in a highly hepatocyte speci®c manner. For various reasons, we were interested in generating an analogous mouse line that expresses rtTA instead of tTA in hepatocytes. Thus, the fusion between P LAP and the gene encoding the novel transactivator rtTA2 S -S2 (15) was used for transgenesis resulting in seven DNA positive animals of which ®ve transmitted the transgene. When crossed with individuals of the LC-1 line, noninvasive luciferase monitoring (23) in presence and absence of Dox (2 mg/ml in drinking water) revealed four lines where the luciferase gene was not activatable. By contrast, in one line designated rTA LAP -1 the antibiotic induced high activity. When luciferase was measured in extracts of isolated organs of double transgenic rTA LAP -1/LC-1 mice, high values were, as expected, found in liver, but also in kidney. As seen in Figure 2 , in absence of Dox, luciferase values are at the level of instrumental background (~1 r.l.u./mg protein). Upon induction by Dox, all organ extracts examined show a low luciferase activity which is, however, 2 to 3 orders of magnitude below the values observed in liver and kidney. Our data show that the luc gene is shut off tightly in the non-induced state in all tissues, while, upon induction, it is activated over 3 to 5 orders of magnitude in liver and kidney, respectively (Fig. 2) . Examination of rTA LAP -1/nZL-2 double transgenic animals where the lacz gene is under control of P tet bi-1 revealed that every hepatocyte is stained demonstrating that in rTA LAP -1 mice P LAP is not subjected to position effect variegation in the liver (data not shown). Moreover, induction of luciferase expression in rTA LAP -1/LC-1 animals is rapid as luciferase activity can be monitored within 1 h after i.p. injection of 2 mg of Dox (23) .
Doxycycline controlled CRE expression
Even though it was anticipated that cre and luc are coregulated by Dox (23), the usefulness of the LC-1 mouse line obviously depends on the tightness of CRE expression in the OFF state and the intracellular level of CRE upon induction which would ensure ef®cient recombination at the target site. By using the R26R (20) indicator mouse line where constitutive b-galactosidase synthesis via the endogenous ROSA26 promoter is prevented at the transcriptional level by a loxP-¯anked stop sequence, we have examined the functional CRE background of the LC-1 mouse line. Thus, LC-1/R26R double transgenic animals were histologically analyzed for b-galactosidase activity at day E14 of embryonic development (data not shown) and through adulthood. As exempli®ed in Figure 3 , no signs of recombination were detected in several up to 14-month-old animals in any tissue examined, con®rm-ing the tight control of the bidirectional transcription unit in the LC-1 locus as already indicated by the barely detectable luciferase activities in LC-1 animals.
The same picture emerges when triple transgenic animals, where tTA or rtTA is expressed tissue-speci®cally, are examined in the OFF state. As exempli®ed for liver, kidney and lung, there is no sign of recombination in rTA LAP -1/LC-1/ R26R animals in the OFF state as shown by in situ b-galactosidase monitoring (Fig. 4) and by PCR of respective DNA (Fig. 5 ). In contrast, two i.p. injections (2 mg of Dox each) spaced 24 h apart convert the inactive lacz into an active gene within less than 48 h via recombination (Figs 4 and 5) . This experiment revealed that in the rTA LAP -1 mouse line the transactivator is produced not only in hepatocytes but also in some additional rather well de®ned cell populations of the kidney such as the cortical proximal tubules and of TAL pro®les of the inner stripe. Moreover, there is also sporadic expression in a minor fraction of bronchial epithelial cells which, however, do not include clara or mucous epithelial cells (Fig. 4) . This particular pattern of CRE activity is obviously due to position effects governing the activity of the LAP promoter in the rTA LAP -1 mouse line, as comparisons with TA LAP -1 and TA LAP -2 mouse lines (17) con®rm (data not shown). The high levels of luciferase activity (r.l.u./mg) detected in the kidney, where only a fraction of cells produce the transactivator, suggest that a lower expression of the transactivator in hepatocytes of rTA LAP -1 animals may limit luciferase expression. This phenomenon has been observed previously (17) .
When LC-1 mice were crossed with individuals of the TA CamK -1 mouse line (line B in 24) which constitutively produce tTA in neurons of the forebrain, Dox dependent e134
co-regulation of CRE and luciferase expression was demonstrated by assaying luciferase activity in tissue extracts and by immunostaining of CRE in situ (Fig. 6) .
Accessibility of the LC-1 locus for tTA/rtTA
Detailed analysis of liver sections as depicted in Figure 4 shows that in rTA LAP -1/LC-1/R26R animals, recombination has occurred in every hepatocyte. Obviously, none of the three mouse lines gives rise to position effect variegation in hepatocytes implying that every hepatocyte produces rtTA which, when activated by Dox, can access the respective LC-1 locus to express CRE which in turn is capable of catalyzing a recombination event at the ROSA26 locus in every cell. These results show that at least in hepatocytes the LC-1 mouse line is not subjected to PEV and that CRE levels are induced that lead to a rapid and complete deletion of an appropriately loxPanked DNA segment. This reasoning is supported by data obtained with two sets of triple transgenic animals (TA LAP -1/ LC-1/polb¯o x and mEG2/LC-1/polb¯o x ) where complete deletion of the loxP-¯anked beta polymerase was demonstrated in hepatocytes and T lymphocytes by Southern blot analysis (14) .
DISCUSSION
Here, we describe two transgenic mouse lines of which the ®rst one, the LC-1, allows us to superimpose an effective and reliable temporal control onto CRE mediated recombination via the Tet regulatory system, whereas the second one, the rTA LAP -1, con®nes Tet regulation via rtTA rather exclusively to hepatocytes, some subsets of kidney cells and a minute population of cells in the bronchial epithel.
The LC-1 mouse line will expand the applications of conditional mutagenesis. A prerequisite for regulating a gene of interest such as the cre gene tightly and over a suf®cient range is the integration of the P tet -cre transcription unit into an appropriate chromosomal site, where no outside activation of P tet occurs while high levels of expression can be achieved upon induction. Indeed, the locus identi®ed in our LC-1 mouse lines appears to ful®ll all criteria required. Triple transgenic 6±8-month-old mice were examined for b-galactosidase expression in the uninduced (left part, ±Dox) and the induced (right part, +Dox) state. For CRE induction, animals were injected i.p. with Dox (2Q 2 mg, 24 h interval). Five days after CRE induction, mice were sacri®ced for histological examination. X-gal staining revealed speci®c patterns in liver, kidney and lung tissue which re¯ect the activity of the LAP promoter in the rTA LAP -1 mouse line. In situ staining as in Figure 3 . Figure 5 . PCR analysis of DNA of triple transgenic rTA LAP -1/LC-1/R26R animals. DNA isolated from ®xed tissue used for the in situ histology shown in Figure 4 was subjected to 38 ampli®cation cycles. Only the DNA of animals where CRE was induced via Dox shows the expected recombination product of 600 bp generated by the primers R26F2 and lacZ4. lacz, control ampli®cation product, demonstrating the presence of the lacz gene; wt, DNA from nontransgenic animals; M, molecular weight marker. First, with the exception discussed below, we have not detected CRE recombination in any tissue and at any time during development and adulthood of up to 14-month-old LC-1/R26R double transgenic animals demonstrating that the bidirectional cre±luc transcription unit embedded in the LC-1 locus generates no or only subfunctional and, thus, negligible amounts of CRE which agrees with the barely measurable luciferase activities monitored in the various organs of the animals. Corresponding results were obtained with rTA LAP -1/ LC-1/R26R triple transgenic mice. Thus, in the OFF state the LC-1 locus appears to be ubiquitously silent.
Second, expression of CRE and luciferase is inducible in all cell types and tissues examined. For example, by crossing LC-1 mice with individuals of the rTA CMV -3 line, luciferase activity is detected in all tissues/organs where P hCMV is known to be active ( Fig. 2; 17) . Moreover, luciferase is induced in hepatocytes, neurons, kidney cells and T lymphocytes as analyses of respective LC-1 double transgenic animals show. In the LC-1 locus, the cre and the luc gene are transcribed at about the same rate (23) . It, therefore, can be safely assumed that CRE is produced in all cells where luciferase can be monitored. This is supported by immunostaining of CRE which was positive in all tissues analyzed, namely in hepatocytes, neurons (Fig. 6 ), kidney cells (data not shown) and T lymphocytes (14) . Moreover, in all these cell types, ef®cient CRE mediated recombination was detected. Therefore, given the present set of data, it appears not unlikely that LC-1 animals are capable of producing CRE and, thus, of mediating recombination in many, possibly all cell types provided that tTA or rtTA is expressed in the respective cell.
Third, our data obtained with rTA LAP -1/LC-1/R26R mice show that upon induction CRE recombination occurs rapidly in all hepatocytes. Accordingly, the LC-1 locus is accessible for tTA/rtTA in every cell. Similar results were obtained in pyramidal cells of the hippocampus (H.Krestel, personal communication). Apparently, the LC-1 locus does not cause PEV in these very different cell types, and it will be interesting to learn from future studies whether absence of PEV will be another general feature of this locus.
The second mouse line characterized here (rTA LAP -1) demonstrates that CRE and luciferase controlled by P tet bi-1 can be regulated over several orders of magnitude via Dox in highly speci®c cell populations while not causing any measurable activity of luciferase or CRE in the uninduced state. The ®nding that in the uninduced state even 6±8-monthold triple transgenic animals (rTA LAP -1/LC-1/R26R) show no sign of recombination in cells producing rtTA2 S -S2 demonstrates the high discrimination potential of this transactivator.
One observation should, however, not go unmentioned here. We have occasionally detected a very small number of X-gal positive cells in kidney and heart sections of some, but not all individuals of a litter of LC-1/R26R double transgenic animals. While this could well be an artefact indicating endogenous activities for X-gal production, it could also re¯ect individual variations in background activity of the LC-1 locus. As described previously (17) , up to 5-fold differences in expression levels can be measured among littermates of transgenic animals. We attribute these differences to epigenetic variations among individuals, a point to be kept in mind when changing the genetic background via breeding.
In conclusion, the properties of the genomic site, where the P tet bi-1 controlled cre gene is integrated and co-regulated with the luc gene, make the LC-1 mouse line an interesting and probably widely applicable experimental tool for controlling CRE recombination in vivo. Moreover, the fact that the expression of CRE cannot only be tightly suppressed, thus preventing undesired background, but also induced to high levels may be of particular value. Various reports suggest that recombination ef®ciency also depends on the topography of the loxP-¯anked DNA within the chromatin context. Short exposure of such sites to high levels of CRE may be a suitable approach for achieving ef®cient and complete recombination while avoiding side effects of high constitutive levels of recombinase. Finally, considering the two growing`zoos' of transgenic mouse lines containing either tTA/rtTA genes under the control of various tissue speci®c promoters or a wide variety of loxP-¯anked genes, the LC-1 mouse line provides an attractive link for exploiting the two worlds of transgenic mice.
